ANI Pharmaceuticals ANIP Generic pharmaceutical products — Net Revenues

Similar metrics at other companies

VTRSGenerics — Net Sales

$1.18B+4.5%

BCRXProduct sales, net — Total revenues

$151.4M+5.3%

AUPHNet product sales — Revenue

$73.56M+22.7%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

BMYNet product sales — Total Revenues

$11.17B+2.6%

TARSProduct sales, net — Total revenues

$145.39M+85.6%

Questions, answered.

What is ANI Pharmaceuticals's generic pharmaceutical products — net revenues?

ANI Pharmaceuticals (ANIP) reported generic pharmaceutical products — net revenues of $105.4M in Q1 2026.

How has ANI Pharmaceuticals's generic pharmaceutical products — net revenues changed year-over-year?

ANI Pharmaceuticals's generic pharmaceutical products — net revenues increased by 6.8% year-over-year, from $98.68M to $105.4M.

What is the long-term trend for ANI Pharmaceuticals's generic pharmaceutical products — net revenues?

Over 4 years (2021 to 2025), ANI Pharmaceuticals's generic pharmaceutical products — net revenues has grown at a 27.8% compound annual growth rate (CAGR), from $143.95M to $384.11M.

What does generic pharmaceutical products — net revenues mean?

This metric represents the total gross sales of generic pharmaceutical products after accounting for returns, allowances, and rebates. It serves as a primary indicator of the company's market penetration and competitive positioning within the off-patent drug sector. Growth in this segment reflects the successful commercialization of generic formulations and the ability to maintain market share against other generic manufacturers.